CLL
News
CLL: Genetic aberrations predict poor treatment response in elderly
Key clinical point: In elderly patients who have chronic lymphocytic leukemia and comorbidities, several genetic abnormalities predict a poor...
Conference Coverage
CAR T-cell therapy eyed for CLL patients with residual disease
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy....
Conference Coverage
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
Key clinical point: Progression-free survival was improved for poor prognosis patients with relapsed chronic lymphocytic leukemia when idelalisib...
News
Acalabrutinib shows efficacy as monotherapy in untreated CLL
Key clinical point: Acalabrutinib, which has shown efficacy in relapsed CLL, has now shown efficacy as a monotherapy for patients with previously...
News
Ibrutinib at below standard dose may achieve good survival in CLL
Key clinical point: Ibrutinib given at doses lower than the standard dose of 420 mg/day may achieve comparable overall survival and progression-...
Conference Coverage
Maintenance rituximab extends progression-free but not overall survival in CLL
Key clinical point: Progression-free survival, but not overall survival, was improved after 2 years of maintenance immunotherapy with rituximab....
Conference Coverage
Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
Conference Coverage
Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib
Key clinical point: Venetoclax can achieve responses in patients who are refractory to ibrutinib. Major finding: The overall response rate was 61...
News
CAR T-cell start-up launched
News
‘Universal’ CAR T cell may overcome limitations
News
New single-tube assay detects one CLL cell in 1 million leukocytes
Key clinical point: Chronic lymphocytic leukemia cells can be identified at levels as low as 0.0010% with a newly developed and validated single-...